HBV vaccination lust recommended for HBV–susceptible chronic hepatitis C patients: Warning on account of a case

Hepatit B veya hepatit C virüsü enfeksiyonları akut ve kronik karaciğer hastalığının son derece yaygın nedenleri olup bu iki virusün birliktelikleri de nadir değildir. Her iki hastalık da, birlikte veya tek başına, dünyada önemli bir sağlık sorunudur. Burada kronik hepatit C virüs enfeksiyonu olan bir hastada gelişen akut hepatit B enfeksiyonu sunuldu. Hepatit B aşısının atlanmış olması hastaya sorun yaratmıştı. Hastaya hepatit B asşısı önerilmeliydi. Kronik hepatit C’li hastalar hepatit B’ye ve hatta hepatit A’ya karşı duyarlı iseler aşı olmalıdırlar. Benzer şekilde, tüm kronik hepatit B’li hastalar da hepatit A aşısı için değerlendirilmelidirler. Bu yazıda, bir vaka nedeniyle, aşılamanın önemine dikkat çekmek istendi.

HBV'ye duyarlı kronik hepatit C hastalarında HBV aşılaması mutlaka önerilmelidir: Bir olgu nedeniyle uyarı

Infections by the hepatitis B or hepatitis C virus are extremely common causes of acute and chronic liver disease, and coexistence of the two viruses is not uncommon. Both of two diseases, together or alone, are important health problem on the world. Here, in a patient with chronic hepatitis C virus infection who developed acute hepatitis B virus infection was reported. She was in trouble because of skipped hepatitis B vaccination. The patient have been recommended to receive vaccinations against hepatitis B. Patients with chronic hepatitis C should immunized against hepatitis B virus and even hepatitis A virus. Whole chronic hepatitis B patients also should be evaluated for hepatitis A vaccine. In this paper, due to a case, were asked to draw attention to the importance of vaccination.

PDF

___

1. Alberti A, Pontisso P, Chemello L, Fattovich G, Benvegnu L, Belussi F, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol.1995; 22(1 Suppl): 38–41.
2. Guptan RC, Thakur V, Malhotra V, Sarin SK. Clinical implications of viral activity in dual infection with hepatitis B and C in chronic liver disease. J Assoc Physicians India.2002; 50: 651–655.
3. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost–Bezeaux F, et al. Characteristics of patient with dual infection by hepatitis B and C viruses. J Hepatol.1998; 28: 27–33.
4. Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology.2002; 36:1285–1291.
5. Ishikawa T, Ichida T, Yamagiwa S, Sugahara S, Uehara K, Okoshi S, et al. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol. 001; 16: 1274–1281.
6. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer.1999; 85: 2132–2137.
7. Marusawa H, Osaki Y, Kimura T, Ito K, Yamashita Y, Eguchi T, et al. High prevalence of anti–hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut.1999; 45: 284–288.
8. Chlabicz S, Lapinski TW, Grzeszczuk A, Prokopowicz D. Four–year follow up of hepatitis C patients vaccinated against hepatitis B virus. World J Gastroenterol.2005; 11: 1798–1801.